JAZZ Stock Gets Increased EPS Forecast from Zacks Research

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Stock analysts at Zacks Research upped their Q3 2026 earnings estimates for shares of Jazz Pharmaceuticals in a note issued to investors on Friday, October 23rd. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings of ($5.14) per share for the quarter, up from their prior forecast of ($5.24). The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $18.24 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q4 2026 earnings at $5.28 EPS, FY2026 earnings at $10.28 EPS and Q4 2027 earnings at $5.11 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same period in the prior year, the company earned ($8.25) earnings per share. The firm’s revenue for the quarter was up 15.5% on a year-over-year basis.

Several other research analysts have also recently issued reports on JAZZ. Citigroup started coverage on Jazz Pharmaceuticals in a report on Wednesday, September 30th. They issued a “buy” rating and a $325.00 price target on the stock. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $337.00 price objective for the company. Deutsche Bank Aktiengesellschaft lifted their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Piper Sandler lifted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $290.85.

Jazz Pharmaceuticals Trading Down 3.9%

Jazz Pharmaceuticals stock opened at $205.70 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The firm has a market cap of $13.35 billion, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 0.26 and a beta of 0.37. Jazz Pharmaceuticals has a 1 year low of $128.80 and a 1 year high of $266.38. The firm’s 50 day moving average price is $235.29 and its two-hundred day moving average price is $215.34.

Insider Activity

In related news, Director Bruce Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $230.33, for a total value of $1,381,980.00. Following the completion of the transaction, the director owned 345,875 shares of the company’s stock, valued at approximately $79,665,388.75. This trade represents a 1.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president owned 65,686 shares in the company, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,121 shares of company stock worth $24,855,802 in the last quarter. Insiders own 4.10% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of JAZZ. Castleark Management LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth about $9,214,000. Bank of America Corp DE boosted its position in Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after acquiring an additional 99,656 shares during the period. SEB Asset Management AB purchased a new position in Jazz Pharmaceuticals during the 1st quarter valued at about $8,765,000. California Public Employees Retirement System grew its stake in Jazz Pharmaceuticals by 10.6% during the 1st quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock valued at $23,552,000 after acquiring an additional 11,915 shares in the last quarter. Finally, Boston Trust Walden Corp grew its stake in Jazz Pharmaceuticals by 24.1% during the 1st quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock valued at $92,381,000 after acquiring an additional 94,750 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.